Mitochondria as therapeutic targets in assisted reproduction.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical studies without systematic review methodology.
PubMed 39066614 · doi:10.1093/humrep/deae170
What was done
This narrative review synthesizes the role of mitochondrial quality control in oocyte developmental competence and evaluates emerging therapeutic interventions for assisted reproduction. It reviews mitochondrial-targeted pharmacological agents (coenzyme Q10, mitoquinone, rapamycin, and nicotinamide mononucleotide) and mitochondrial replacement therapies, including autologous germline mitochondrial energy transfer, maternal spindle transfer, and pronuclear transfer.
What was found
The abstract provides no numerical findings or effect sizes. It reports qualitatively that autologous germline mitochondrial energy transfer failed to show significant benefits in clinical trials, whereas maternal spindle transfer showed promising early outcomes. Pharmacological agents demonstrated potential to target mitochondrial function, but quantifiable clinical outcomes are not presented.
Why it matters
Identifying targeted interventions for mitochondrial dysfunction addresses a major biological mechanism underlying oocyte aging and reproductive failure, while highlighting pathways for preventing transmission of inherited mitochondrial disorders.
Limits
The abstract describes a narrative review without systematic search criteria or meta-analytic data. Specific sample sizes and outcome magnitudes are omitted, most pharmacological strategies remain experimental, and mitochondrial replacement techniques face safety uncertainties, limited trial data, and substantial regulatory restrictions.
Cited by
- supports Mitochondrial genes and function are involved in meiotic spindle formation and embryo development.